Informations générales (source: ClinicalTrials.gov)
Tumor Treating Fields General Routine Clinical Care in Newly Diagnosed Glioblastoma Patients: a French Prospective Non-Interventional Study - TIGER France (TIGER France)
Observational
NovoCure Ltd. (Voir sur ClinicalTrials)
janvier 2024
janvier 2029
12 avril 2025
This prospective multicenter non-interventional study (NIS) aims at confirming the
survival benefit of Optune Gio® - in terms of OS and PFS - and describing device usage
(compliance will be measured through patient's usage report, recorded by each device) and
impact on QoL, in a real-life setting in France, in a large cohort of participants with
newly diagnosed GBM who completed radiotherapy and concomitant TMZ after surgery and
initiatingtreatment with Optune Gio® device together with maintenance TMZ.
A special emphasis will be given to the evaluation of QoL and the impact of Optune Gio®
on daily life, considering the limited life expectancy of these patients, the symptom
burden and significant disease-related disability.
Etablissements
Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
---|---|---|---|---|---|
AP-HP - Hôpital La Pitié-Salpêtrière | GH PITIE SALPETRIERE | Contact (sur clinicalTrials) | |||
CLCC INSTITUT GUSTAVE ROUSSY | inst INSTITUT GUSTAVE ROUSSY | Contact (sur clinicalTrials) | |||
HOPITAL FOCH | Hop HOPITAL FOCH | Contact (sur clinicalTrials) | |||
Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
Centre Hospitalier La Timone - 13000 - Marseille - France | CH LA TIMONE | Contact (sur clinicalTrials) | |||
Centre Lutte Contre Le Cancer Jean Perrin - 63011 - Clermont-Ferrand - France | CRLCC CENTRE LUTTE CONTRE LE CANCER JEAN PERRIN | Contact (sur clinicalTrials) | |||
Ch Regional Orleans - 45067 - Orléans - France | CHR CH REGIONAL ORLEANS | Contact (sur clinicalTrials) | |||
Chu Amiens Picardie - 80000 - Amiens - France | CHU AMIENS PICARDIE | Contact (sur clinicalTrials) | |||
Chu Brest Hopital Morvan - 29609 - Brest - France | CHU BREST HOPITAL MORVAN | Contact (sur clinicalTrials) | |||
Chu de Grenoble Alpes - 38700 - La Tronche - France | chu CHU DE GRENOBLE ALPES | Contact (sur clinicalTrials) | |||
CHU de Nice - 06000 - Nice - France | CHU CHU de Nice | Contact (sur clinicalTrials) | |||
CHU de Nîmes - HOPITAL CAREMEAU - 30000 - Nîmes - France | CHU CHU de Nîmes - HOPITAL CAREMEAU | Contact (sur clinicalTrials) | |||
Chu de Saint Etienne - 42271 - Saint-Priest-en-Jarez - France | CHU CHU DE SAINT ETIENNE | Contact (sur clinicalTrials) | |||
Chu Saint Andre - 33000 - Bordeaux - France | CHU SAINT ANDRE | Contact (sur clinicalTrials) | |||
CRLCC - Centre Eugène Marquis - 35000 - Rennes - France | CRLCC Centre Eugène Marquis | Contact (sur clinicalTrials) | |||
Crlcc Francois Baclesse - 14000 - Caen - France | CRLCC FRANCOIS BACLESSE | Contact (sur clinicalTrials) | |||
Crlcc Georges Francois Leclerc - 21000 - Dijon - France | CRLCC GEORGES FRANCOIS LECLERC | Contact (sur clinicalTrials) | |||
Crlcc Henri Becquerel - 76000 - Rouen - France | CRLCC HENRI BECQUEREL | Contact (sur clinicalTrials) | |||
Hia Sainte Anne - 83000 - Toulon - France | hia HIA SAINTE ANNE | Contact (sur clinicalTrials) | |||
Hopital Neurologie Pierre Wetrheimer - 69500 - Bron - France | Hop HOPITAL NEUROLOGIE PIERRE WETRHEIMER | Contact (sur clinicalTrials) | |||
Hopital Roger Salengro - 59000 - Lille - France | HOPITAL ROGER SALENGRO | Contact (sur clinicalTrials) | |||
Hopital Saint Louis - 75010 - Paris - France | HOPITAL SAINT LOUIS | Contact (sur clinicalTrials) | |||
Institut Claudius Regaud - 31059 - Toulouse - France | inst INSTITUT CLAUDIUS REGAUD | Contact (sur clinicalTrials) | |||
Institut du Cancer de Montpellier - Val d'Aurelle - 34298 - Montpellier - France | inst Institut du Cancer de Montpellier - Val d'Aurelle | Contact (sur clinicalTrials) | |||
Institut Sainte-Catherine - 84000 - Avignon - France | inst INSTITUT SAINTE-CATHERINE | Contact (sur clinicalTrials) |
Critères
Tous
Inclusion Criteria:
- Participant aged ≥ 18 years old.
- Participant with newly diagnosed GBM.
- Participant who completed radiochemotherapy after surgery or biopsy.
- Participant within first 2 cycles of maintenance TMZ.
- Participant for whom the physician has decided to initiate treatment with Optune®
according to Instruction For Use or medical guidelines.
- Participant aged ≥ 18 years old.
- Participant with newly diagnosed GBM.
- Participant who completed radiochemotherapy after surgery or biopsy.
- Participant within first 2 cycles of maintenance TMZ.
- Participant for whom the physician has decided to initiate treatment with Optune®
according to Instruction For Use or medical guidelines.
- Participant currently participating in a prospective clinical trial studying a
different treatment than the one studied in this current prospective study.
- Patient currently breastfeeding.
- Patient who is pregnant, thinks she might be pregnant or is trying to become
pregnant. Patient of childbearing potential must use a contraceptive method for the
whole duration of their participation in the study.
- Patient suffering from a significant neurological disease (primary epilepsy,
dementia, progressive degenerative neurological disorder, meningitis or
encephalitis, hydrocephalus associated with increased intracranial pressure).
- Patient with a known sensitivity to conductive hydrogels, such as gel used with
electrocardiogram (ECG) or transcutaneous electrical nerve stimulation (TENS)
electrodes.
- Patient with an active implanted medical device, a cranial defect (such as a missing
bone that has not been replaced) or bullet fragments. Active electronic devices
include, for example, deep brain stimulators, spinal cord stimulators, vagus nerve
stimulators, pacemakers and defibrillators.
- Participant being deprived of liberty by a judicial or administrative decision, or
who is under a measure of legal protection (e.g. guardianship or curatorship).